Secretary Vaidya Rajesh Kotecha has urged senior officials to strive for the successful attainment of targets during the campaign
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Subscribe To Our Newsletter & Stay Updated
